Cagrilintide / CagriSema

Mechanism

Cagrilintide is a long-acting analog of amylin (also called islet amyloid polypeptide, IAPP), a 37-amino-acid peptide co-secreted with insulin from pancreatic beta cells in response to meals.

Native amylin contributes to glucose and weight homeostasis by:

• Slowing gastric emptying (reducing post-meal glucose excursion)
• Suppressing inappropriate post-meal glucagon
• Promoting satiety through central nervous system action (area postrema)

Native amylin has a half-life of minutes and aggregates into amyloid fibrils that limit therapeutic use. Cagrilintide is engineered to resist aggregation and to extend the half-life via fatty-acid acylation, supporting once-weekly subcutaneous dosing.

The CagriSema premise is that amylin and GLP-1 work through partially overlapping but distinct neural circuits in satiety regulation. The amylin signal acts primarily through the area postrema; the GLP-1 signal acts through hypothalamic and brainstem circuits. Combining them recruits more of the satiety system simultaneously. Mechanistically this is reasonable; the empirical question is whether the additive clinical effect is large enough to justify the increased complexity (and potentially worse tolerability) of a combination product.

What the evidence shows

Phase 2 — Enebo LB et al, Lancet 2021:

A 20-week trial in adults with overweight/obesity comparing cagrilintide alone (multiple doses), semaglutide 2.4 mg alone, and CagriSema combination. CagriSema produced 17.1% weight loss at 32 weeks (extended portion); semaglutide alone produced 9.8%; cagrilintide alone produced 8.0%.

Phase 2 in T2D:

Smaller program showing improvements in HbA1c and weight that exceed semaglutide alone, consistent with the obesity result.

Phase 3 — REDEFINE program:

Multiple ongoing Phase 3 trials. Early reads from REDEFINE-1 (general obesity) have shown weight loss in the 20% range — strong but at the lower end of what Phase 2 led readers to expect. REDEFINE-2 (obesity with T2D) reading out separately. Cardiovascular outcomes program is also planned but later.

The Phase 3 reads are not as unambiguously positive as the tirzepatide Phase 3 reads were. The drug works; the question is whether the additive effect over semaglutide alone is large enough to justify the complexity, given that semaglutide is a single-injection product with a known profile.

Why we’re holding at Promising:

Phase 2 results were impressive but the confirmatory Phase 3 reads are still maturing. The mechanism is sound. The commercial story (Novo Nordisk, the same sponsor as semaglutide and liraglutide) is well-resourced. We expect this to graduate to Established in 2026–2027 if the Phase 3 reads continue to confirm; we’ll re-evaluate at the scheduled re-review.

Dosing literature

There is no approved dose because the drug is not yet approved. Trial protocols have used:

• Cagrilintide alone: 0.16 mg, 0.30 mg, 0.60 mg, 1.2 mg, 2.4 mg, or 4.5 mg weekly subcutaneous, with titration
• CagriSema: Cagrilintide 2.4 mg + Semaglutide 2.4 mg fixed-dose combination, weekly subcutaneous

The CagriSema target dose (2.4 + 2.4) is being studied; depending on Phase 3 data, the approved formulation may use these or other doses.

Risks and adverse events

Common (Phase 2 data):

• Nausea (more frequent with CagriSema than semaglutide alone)
• Vomiting
• Decreased appetite
• Constipation, diarrhea, dyspepsia
• Injection-site reactions

Tolerability vs. semaglutide alone:

The combination has a somewhat worse GI tolerability profile than semaglutide alone, which is the predictable cost of stacking two satiety-affecting drugs. Whether this is offset by the better efficacy depends on patient experience.

Less common but reported:

• Hypoglycemia in patients also on insulin or sulfonylureas
• Fatigue
• Dose-titration-dependent intolerance (some patients cannot reach target dose)

Pre-clinical / theoretical:

Same MTC C-cell tumors-in-rodents class warning as other GLP-1 agonists (semaglutide carries this; cagrilintide as an amylin agonist does not have the same signal but the combination product carries it via the semaglutide component).

The drug is not yet approved. Self-sourced “cagrilintide” sold via gray-market peptide vendors has the same identity and quality concerns as other unapproved peptides — without manufacturing oversight, no certainty about what’s in the vial.

Regulatory status

Expected first regulatory submissions in 2026 if REDEFINE program reads out positively.

Where to get it

The legitimate access path is enrolling in an active clinical trial. Trial sites are listed on ClinicalTrials.gov under the REDEFINE program identifiers.

We do not route readers to any fulfillment partner for cagrilintide or CagriSema. (See How we make money.)

References (selected)

1. Enebo LB et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial. Lancet 2021. PubMed
2. Lau DCW et al. Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. Lancet 2021.
3. ClinicalTrials.gov — REDEFINE program (NCT05567796 and related).
4. Novo Nordisk investor disclosures — Phase 3 timelines.